DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Vorapaxar

Vorapaxar

  • FDA Approves ZONTIVITY™ (Vorapaxar), First-In-Class PAR-1

    FDA Approves ZONTIVITY™ (Vorapaxar), First-In-Class PAR-1

  • Zontivity (Vorapaxar)

    Zontivity (Vorapaxar)

  • Annexes to the Annual Report of the European Medicines Agency 2014

    Annexes to the Annual Report of the European Medicines Agency 2014

  • Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke

    Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke

  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

  • Cholesterol-Rich Microdomains Contribute to PAR1 Signaling in Platelets Despite a Weak Localization of the Receptor in These Microdomains

    Cholesterol-Rich Microdomains Contribute to PAR1 Signaling in Platelets Despite a Weak Localization of the Receptor in These Microdomains

  • 204886Orig1s000

    204886Orig1s000

  • Neuraxial Access Or Peripheral Nerve Procedures)

    Neuraxial Access Or Peripheral Nerve Procedures)

  • Summary of the Risk Management Plan (RMP) for Zontivity (Vorapaxar)

    Summary of the Risk Management Plan (RMP) for Zontivity (Vorapaxar)

  • Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease

    Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease

  • Protocol for Non-Interventional Studies Based on Existing Data TITLE PAGE Document Number: C30445781-01

    Protocol for Non-Interventional Studies Based on Existing Data TITLE PAGE Document Number: C30445781-01

  • Rivaroxaban Effects Illustrate the Underestimated Importance Of

    Rivaroxaban Effects Illustrate the Underestimated Importance Of

  • Zontivity, INN-Vorapaxar

    Zontivity, INN-Vorapaxar

  • Joint Asian Pacific Association Of

    Joint Asian Pacific Association Of

  • Vorapaxar: a New Antiplatelet Therapy

    Vorapaxar: a New Antiplatelet Therapy

  • Express Scripts Canada® Drug Trend Report 2016

    Express Scripts Canada® Drug Trend Report 2016

  • Deaconess Anticoagulant & Antiplatelet Medication Reversal

    Deaconess Anticoagulant & Antiplatelet Medication Reversal

  • Systemic Glucocorticoids in the Treatment of COVID-19 and Risks of Adverse Outcomes in COVID-19 Patients in the Primary and Secondary Care Setting

    Systemic Glucocorticoids in the Treatment of COVID-19 and Risks of Adverse Outcomes in COVID-19 Patients in the Primary and Secondary Care Setting

Top View
  • High-Resolution Crystal Structure of Human Protease-Activated Receptor 1
  • Study Protocol
  • 1 Pharmacodynamic Effects of Vorapaxar As An
  • GI Tables for Anticoagulation Discontinuation & Colonoscopy
  • Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
  • Preventative Medication List
  • Direct Oral Anticoagulant Use: a Practical Guide to Common Clinical Challenges
  • Management of Antithrombotic Agents in Patients Undergoing Flexible Bronchoscopy
  • ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
  • Maintenance Drug List
  • Recent Progress and Market Analysis of Anticoagulant Drugs
  • Vitamin K Antagonist Oral Anticoagulants Clinical Pathway
  • Platelet Concentrates from 5 Donors in ABO Blood-Group-Matched Plasma) Were Obtained from the Dutch Bloodbank (Sanquin)
  • Dental Considerations in Patients Taking New Antiplatelet and Anticoagulant Drugs
  • Vorapaxar Manufacturer: Merck Sharp & Dohme Corp Drug Class1-5
  • Platelet Aggregation Inhibitors (PDF)
  • Peripheral Arterial Disease
  • Outcomes of Paediatric Drug Development from a Labeling


© 2024 Docslib.org    Feedback